Organogenesis Holdings Inc. Files 8-K for Material Agreement

TL;DR

Organogenesis Holdings Inc. signed a major deal on Nov 27, 2024. 8-K filed.

AI Summary

Organogenesis Holdings Inc. entered into a Material Definitive Agreement on November 27, 2024. The filing also includes financial statements and exhibits. The company, previously known as Avista Healthcare Public Acquisition Corp., is incorporated in Delaware and headquartered in Canton, MA.

Why It Matters

This 8-K filing indicates a significant new agreement for Organogenesis Holdings Inc., which could impact its business operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• Organogenesis Holdings Inc. (company) — Registrant
• November 27, 2024 (date) — Date of Earliest Event Reported
• Avista Healthcare Public Acquisition Corp. (company) — Former Company Name
• Delaware (jurisdiction) — State of Incorporation
• Canton, MA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value ORGO Nasdaq Capital Marke
• $4.057 — ing Stockholder for a purchase price of $4.057 per share, which represents the 10-day

Filing Documents

• orgo-20241127.htm (8-K) — 45KB
• orgo-ex10_1.htm (EX-10.1) — 61KB
• 0000950170-24-132248.txt ( ) — 231KB
• orgo-20241127.xsd (EX-101.SCH) — 29KB
• orgo-20241127_htm.xml (XML) — 4KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On November 27, 2024, Organogenesis Holdings Inc. (the "Company") entered into a stock repurchase agreement (the "Stock Repurchase Agreement" and the stock repurchase thereunder, the "Repurchase") with the GN 2016 Family Trust u/a/d August 12, 2016 (the "Selling Stockholder"), pursuant to which the Company will repurchase an aggregate of 500,000 shares of the Company's Class A common stock, par value $0.0001 per share (the "Common Stock") from the Selling Stockholder for a purchase price of $4.057 per share, which represents the 10-day trailing volume weighted average price of the Common Stock as of market close on November 26, 2024. Glenn H. Nussdorf, a member of the board of directors of the Company (the "Board"), is a beneficial owner of the shares held by the GN 2016 Family Trust u/a/d August 12, 2016. The Repurchase and the Stock Repurchase Agreement were approved by the Audit Committee and a Transaction Committee of the Board. The Repurchase was funded by a portion of the proceeds from the Company's previously disclosed sale on November 12, 2024 of its Series A Convertible Preferred Stock to Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P. The Repurchase is expected to close on or around December 3, 2024. The foregoing description of the Repurchase Agreement is not complete and is qualified in its entirety by reference to the Repurchase Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Stock Repurchase Agreement, dated November 27, 2024, by and between Organogenesis Holdings Inc. and GN 2016 Family Trust u/a/d August 12, 2016 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Organogenesis Holdings Inc. By: /s/ Lori Freedman Name: Lori Freedman Title: Chief Administrative and Legal Officer Date: December 2, 2024

View Full Filing

View this 8-K filing on SEC EDGAR